 RedHill Biopharma Accelerates Ongoing U.S. Phase 23 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval The South African Health Products Regulatory Authority SAHPRA has approved the Phase 23 study of once-daily orally-administered RHB-107 upamostat for patients with symptomatic COVID-19 who do not require hospital care - Number of U.S. sites for the study has also been expanded - RHB-107, a novel antiviral serine protease inhibitor targeting human cell factors, is expected to be effective against emerging viral variants - RHB-107 is being developed as a potential treatment with a simple once-daily oral pill in the early course of COVID-19 - In parallel RedHills leading oral COVID-19 therapeutic, opaganib, is being evaluated in a global Phase 23 study in 475 patients hospitalized with severe COVID-19, with top-line results upcoming TEL AVIV, ISREAL and RALEIGH, NC ACCESSWIRE September 13, 2021 RedHill Biopharma Ltd. Nasdaq:RDHL RedHill or the Company, a specialty biopharmaceutical company, today announced that South Africa has joined the U.S. in approving the Phase 23 study with novel, once-daily, orally-administered pill RHB-107 upamostat 1 for non-hospitalized patients with symptomatic COVID-19. 